

Taiwan approves manufacturing of Medigen's COVID-19 vaccine

19 July 2021 | News

Medigen's COVID-19 vaccine is designed for use in adults aged 20 or older



The Food and Drug Administration of the Ministry of Health and Welfare in Taiwan has approved the manufacturing of Medigen's COVID-19 vaccine.

Taiwan-based Medigen Vaccine Biologics Corp's (MVC) COVID-19 vaccine is designed for use in adults aged 20 or older, who will get two doses of the vaccine 28 days apart to build protection against COVID-19.

MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax plus aluminum hydroxide. The S-2P antigen is a trimeric and prefusion-stable recombinant spike protein developed by the U.S. NIH. MVC has obtained a global technology license for S-2P from the U.S. Vaccine Research Center at National Institutes of Health (NIH).

MVC established the production platform of MVC-COV1901 and based on MVC's preclinical, Phase 1 and Phase 2 clinical study data, MVC-COV1901 has shown robust safety and promising immunogenicity responses.